Recurrent venous thromboembolism in anticoagulated patients with cancer: management and short-term prognosis.
Identifieur interne : 002C54 ( PubMed/Curation ); précédent : 002C53; suivant : 002C55Recurrent venous thromboembolism in anticoagulated patients with cancer: management and short-term prognosis.
Auteurs : S. Schulman [Canada] ; M. Zondag [Canada] ; L. Linkins [Canada] ; S. Pasca [Italie] ; Y W Cheung [Pays-Bas] ; M. De Sancho [États-Unis] ; A. Gallus [Australie] ; R. Lecumberri [Espagne] ; S. Molnar [Argentine] ; W. Ageno [Italie] ; G. Le Gal [France] ; A. Falanga [Italie] ; E. Huleg Rdh [Suède] ; S. Ranta [Suède] ; P. Kamphuisen [Pays-Bas] ; P. Debourdeau [France] ; V. Rigamonti [Suisse] ; T L Ortel [États-Unis] ; A. Lee [Canada]Source :
- Journal of thrombosis and haemostasis : JTH [ 1538-7836 ] ; 2015.
Descripteurs français
- KwdFr :
- Adulte d'âge moyen, Anticoagulants (administration et posologie), Anticoagulants (effets indésirables), Enregistrements, Estimation de Kaplan-Meier, Facteurs de risque, Facteurs temps, Femelle, Humains, Hémorragie (), Héparine bas poids moléculaire (administration et posologie), Héparine bas poids moléculaire (effets indésirables), Loi du khi-deux, Modèles de hasards proportionnels, Mâle, Récidive, Résultat thérapeutique, Substitution de médicament, Sujet âgé, Thromboembolisme veineux (diagnostic), Thromboembolisme veineux (mortalité), Thromboembolisme veineux (sang), Thromboembolisme veineux (traitement médicamenteux), Thromboembolisme veineux (étiologie), Tumeurs (), Tumeurs (anatomopathologie), Tumeurs (mortalité), Tumeurs (sang), Vitamine K (antagonistes et inhibiteurs), Warfarine (administration et posologie), Warfarine (effets indésirables), Études prospectives, Études rétrospectives.
- MESH :
- administration et posologie : Anticoagulants, Héparine bas poids moléculaire, Warfarine.
- anatomopathologie : Tumeurs.
- antagonistes et inhibiteurs : Vitamine K.
- diagnostic : Thromboembolisme veineux.
- effets indésirables : Anticoagulants, Héparine bas poids moléculaire, Warfarine.
- mortalité : Thromboembolisme veineux, Tumeurs.
- sang : Thromboembolisme veineux, Tumeurs.
- traitement médicamenteux : Thromboembolisme veineux.
- étiologie : Thromboembolisme veineux.
- Adulte d'âge moyen, Enregistrements, Estimation de Kaplan-Meier, Facteurs de risque, Facteurs temps, Femelle, Humains, Hémorragie, Loi du khi-deux, Modèles de hasards proportionnels, Mâle, Récidive, Résultat thérapeutique, Substitution de médicament, Sujet âgé, Tumeurs, Études prospectives, Études rétrospectives.
English descriptors
- KwdEn :
- Aged, Anticoagulants (administration & dosage), Anticoagulants (adverse effects), Chi-Square Distribution, Drug Substitution, Female, Hemorrhage (chemically induced), Heparin, Low-Molecular-Weight (administration & dosage), Heparin, Low-Molecular-Weight (adverse effects), Humans, Kaplan-Meier Estimate, Male, Middle Aged, Neoplasms (blood), Neoplasms (complications), Neoplasms (mortality), Neoplasms (pathology), Proportional Hazards Models, Prospective Studies, Recurrence, Registries, Retrospective Studies, Risk Factors, Time Factors, Treatment Outcome, Venous Thromboembolism (blood), Venous Thromboembolism (diagnosis), Venous Thromboembolism (drug therapy), Venous Thromboembolism (etiology), Venous Thromboembolism (mortality), Vitamin K (antagonists & inhibitors), Warfarin (administration & dosage), Warfarin (adverse effects).
- MESH :
- chemical , administration & dosage : Anticoagulants, Heparin, Low-Molecular-Weight, Warfarin.
- chemical , adverse effects : Anticoagulants, Heparin, Low-Molecular-Weight, Warfarin.
- chemical , antagonists & inhibitors : Vitamin K.
- blood : Neoplasms, Venous Thromboembolism.
- chemically induced : Hemorrhage.
- complications : Neoplasms.
- diagnosis : Venous Thromboembolism.
- drug therapy : Venous Thromboembolism.
- etiology : Venous Thromboembolism.
- mortality : Neoplasms, Venous Thromboembolism.
- pathology : Neoplasms.
- Aged, Chi-Square Distribution, Drug Substitution, Female, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Proportional Hazards Models, Prospective Studies, Recurrence, Registries, Retrospective Studies, Risk Factors, Time Factors, Treatment Outcome.
Abstract
Recommendations for management of cancer-related venous thromboembolism (VTE) in patients already receiving anticoagulant therapy are based on low-quality evidence. This international registry sought to provide more information on outcomes after a breakthrough VTE in relation to anticoagulation strategies.
DOI: 10.1111/jth.12955
PubMed: 25851122
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002D29
Links to Exploration step
pubmed:25851122Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Recurrent venous thromboembolism in anticoagulated patients with cancer: management and short-term prognosis.</title>
<author><name sortKey="Schulman, S" sort="Schulman, S" uniqKey="Schulman S" first="S" last="Schulman">S. Schulman</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Medicine, McMaster University, Hamilton, ON, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Medicine, McMaster University, Hamilton, ON</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Zondag, M" sort="Zondag, M" uniqKey="Zondag M" first="M" last="Zondag">M. Zondag</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Medicine, McMaster University, Hamilton, ON, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Medicine, McMaster University, Hamilton, ON</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Linkins, L" sort="Linkins, L" uniqKey="Linkins L" first="L" last="Linkins">L. Linkins</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Medicine, McMaster University, Hamilton, ON, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Medicine, McMaster University, Hamilton, ON</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Pasca, S" sort="Pasca, S" uniqKey="Pasca S" first="S" last="Pasca">S. Pasca</name>
<affiliation wicri:level="1"><nlm:affiliation>Center for Hemorrhagic and Thrombotic Disease, University Hospital of Udine, Udine, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Center for Hemorrhagic and Thrombotic Disease, University Hospital of Udine, Udine</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Cheung, Y W" sort="Cheung, Y W" uniqKey="Cheung Y" first="Y W" last="Cheung">Y W Cheung</name>
<affiliation wicri:level="1"><nlm:affiliation>Academic Medical Centre, University of Amsterdam, Amsterdam, the Netherlands.</nlm:affiliation>
<country xml:lang="fr" wicri:curation="lc">Pays-Bas</country>
<wicri:regionArea>Academic Medical Centre, University of Amsterdam, Amsterdam</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="De Sancho, M" sort="De Sancho, M" uniqKey="De Sancho M" first="M" last="De Sancho">M. De Sancho</name>
<affiliation wicri:level="1"><nlm:affiliation>Weill Cornell Medical College, New York, NY, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Weill Cornell Medical College, New York, NY</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Gallus, A" sort="Gallus, A" uniqKey="Gallus A" first="A" last="Gallus">A. Gallus</name>
<affiliation wicri:level="1"><nlm:affiliation>Flinders University, Adelaide, SA, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Flinders University, Adelaide, SA</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Lecumberri, R" sort="Lecumberri, R" uniqKey="Lecumberri R" first="R" last="Lecumberri">R. Lecumberri</name>
<affiliation wicri:level="1"><nlm:affiliation>Hematology Service, University Clinic of Navarra, Pamplona, Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Hematology Service, University Clinic of Navarra, Pamplona</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Molnar, S" sort="Molnar, S" uniqKey="Molnar S" first="S" last="Molnar">S. Molnar</name>
<affiliation wicri:level="1"><nlm:affiliation>Oncology and Hematology Department, Sanatorio Allende, Cordoba, Argentina.</nlm:affiliation>
<country xml:lang="fr">Argentine</country>
<wicri:regionArea>Oncology and Hematology Department, Sanatorio Allende, Cordoba</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Ageno, W" sort="Ageno, W" uniqKey="Ageno W" first="W" last="Ageno">W. Ageno</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Clinical and Experimental Medicine, University of Insubria, Varese, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Department of Clinical and Experimental Medicine, University of Insubria, Varese</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Le Gal, G" sort="Le Gal, G" uniqKey="Le Gal G" first="G" last="Le Gal">G. Le Gal</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Internal Medicine and Chest Diseases, Brest University Hospital, Brest, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Department of Internal Medicine and Chest Diseases, Brest University Hospital, Brest</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Falanga, A" sort="Falanga, A" uniqKey="Falanga A" first="A" last="Falanga">A. Falanga</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Department of Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Huleg Rdh, E" sort="Huleg Rdh, E" uniqKey="Huleg Rdh E" first="E" last="Huleg Rdh">E. Huleg Rdh</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Hematology and Coagulation, Sahlgrenska University Hospital, Gothenburg, Sweden.</nlm:affiliation>
<country xml:lang="fr">Suède</country>
<wicri:regionArea>Department of Hematology and Coagulation, Sahlgrenska University Hospital, Gothenburg</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Ranta, S" sort="Ranta, S" uniqKey="Ranta S" first="S" last="Ranta">S. Ranta</name>
<affiliation wicri:level="1"><nlm:affiliation>Karolinska Institutet, Stockholm, Sweden.</nlm:affiliation>
<country xml:lang="fr">Suède</country>
<wicri:regionArea>Karolinska Institutet, Stockholm</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Kamphuisen, P" sort="Kamphuisen, P" uniqKey="Kamphuisen P" first="P" last="Kamphuisen">P. Kamphuisen</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Vascular Medicine, University Medical Centre Groningen, University of Groningen, Groningen, the Netherlands.</nlm:affiliation>
<country xml:lang="fr" wicri:curation="lc">Pays-Bas</country>
<wicri:regionArea>Department of Vascular Medicine, University Medical Centre Groningen, University of Groningen, Groningen</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Debourdeau, P" sort="Debourdeau, P" uniqKey="Debourdeau P" first="P" last="Debourdeau">P. Debourdeau</name>
<affiliation wicri:level="1"><nlm:affiliation>Oncology Department, Ste Catherine Institute, Avignon, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Oncology Department, Ste Catherine Institute, Avignon</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Rigamonti, V" sort="Rigamonti, V" uniqKey="Rigamonti V" first="V" last="Rigamonti">V. Rigamonti</name>
<affiliation wicri:level="1"><nlm:affiliation>Praxis Bubenberg, Bern, Switzerland.</nlm:affiliation>
<country xml:lang="fr">Suisse</country>
<wicri:regionArea>Praxis Bubenberg, Bern</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Ortel, T L" sort="Ortel, T L" uniqKey="Ortel T" first="T L" last="Ortel">T L Ortel</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Hematology, Duke University Medical Center, Durham, NC, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Division of Hematology, Duke University Medical Center, Durham, NC</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Lee, A" sort="Lee, A" uniqKey="Lee A" first="A" last="Lee">A. Lee</name>
<affiliation wicri:level="1"><nlm:affiliation>Diamond Health Care Centre, University of British Columbia and Vancouver Coastal Health, Vancouver, BC, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Diamond Health Care Centre, University of British Columbia and Vancouver Coastal Health, Vancouver, BC</wicri:regionArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2015">2015</date>
<idno type="RBID">pubmed:25851122</idno>
<idno type="pmid">25851122</idno>
<idno type="doi">10.1111/jth.12955</idno>
<idno type="wicri:Area/PubMed/Corpus">002D29</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002D29</idno>
<idno type="wicri:Area/PubMed/Curation">002C54</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002C54</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Recurrent venous thromboembolism in anticoagulated patients with cancer: management and short-term prognosis.</title>
<author><name sortKey="Schulman, S" sort="Schulman, S" uniqKey="Schulman S" first="S" last="Schulman">S. Schulman</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Medicine, McMaster University, Hamilton, ON, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Medicine, McMaster University, Hamilton, ON</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Zondag, M" sort="Zondag, M" uniqKey="Zondag M" first="M" last="Zondag">M. Zondag</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Medicine, McMaster University, Hamilton, ON, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Medicine, McMaster University, Hamilton, ON</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Linkins, L" sort="Linkins, L" uniqKey="Linkins L" first="L" last="Linkins">L. Linkins</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Medicine, McMaster University, Hamilton, ON, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Medicine, McMaster University, Hamilton, ON</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Pasca, S" sort="Pasca, S" uniqKey="Pasca S" first="S" last="Pasca">S. Pasca</name>
<affiliation wicri:level="1"><nlm:affiliation>Center for Hemorrhagic and Thrombotic Disease, University Hospital of Udine, Udine, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Center for Hemorrhagic and Thrombotic Disease, University Hospital of Udine, Udine</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Cheung, Y W" sort="Cheung, Y W" uniqKey="Cheung Y" first="Y W" last="Cheung">Y W Cheung</name>
<affiliation wicri:level="1"><nlm:affiliation>Academic Medical Centre, University of Amsterdam, Amsterdam, the Netherlands.</nlm:affiliation>
<country xml:lang="fr" wicri:curation="lc">Pays-Bas</country>
<wicri:regionArea>Academic Medical Centre, University of Amsterdam, Amsterdam</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="De Sancho, M" sort="De Sancho, M" uniqKey="De Sancho M" first="M" last="De Sancho">M. De Sancho</name>
<affiliation wicri:level="1"><nlm:affiliation>Weill Cornell Medical College, New York, NY, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Weill Cornell Medical College, New York, NY</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Gallus, A" sort="Gallus, A" uniqKey="Gallus A" first="A" last="Gallus">A. Gallus</name>
<affiliation wicri:level="1"><nlm:affiliation>Flinders University, Adelaide, SA, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Flinders University, Adelaide, SA</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Lecumberri, R" sort="Lecumberri, R" uniqKey="Lecumberri R" first="R" last="Lecumberri">R. Lecumberri</name>
<affiliation wicri:level="1"><nlm:affiliation>Hematology Service, University Clinic of Navarra, Pamplona, Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Hematology Service, University Clinic of Navarra, Pamplona</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Molnar, S" sort="Molnar, S" uniqKey="Molnar S" first="S" last="Molnar">S. Molnar</name>
<affiliation wicri:level="1"><nlm:affiliation>Oncology and Hematology Department, Sanatorio Allende, Cordoba, Argentina.</nlm:affiliation>
<country xml:lang="fr">Argentine</country>
<wicri:regionArea>Oncology and Hematology Department, Sanatorio Allende, Cordoba</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Ageno, W" sort="Ageno, W" uniqKey="Ageno W" first="W" last="Ageno">W. Ageno</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Clinical and Experimental Medicine, University of Insubria, Varese, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Department of Clinical and Experimental Medicine, University of Insubria, Varese</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Le Gal, G" sort="Le Gal, G" uniqKey="Le Gal G" first="G" last="Le Gal">G. Le Gal</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Internal Medicine and Chest Diseases, Brest University Hospital, Brest, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Department of Internal Medicine and Chest Diseases, Brest University Hospital, Brest</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Falanga, A" sort="Falanga, A" uniqKey="Falanga A" first="A" last="Falanga">A. Falanga</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Department of Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Huleg Rdh, E" sort="Huleg Rdh, E" uniqKey="Huleg Rdh E" first="E" last="Huleg Rdh">E. Huleg Rdh</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Hematology and Coagulation, Sahlgrenska University Hospital, Gothenburg, Sweden.</nlm:affiliation>
<country xml:lang="fr">Suède</country>
<wicri:regionArea>Department of Hematology and Coagulation, Sahlgrenska University Hospital, Gothenburg</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Ranta, S" sort="Ranta, S" uniqKey="Ranta S" first="S" last="Ranta">S. Ranta</name>
<affiliation wicri:level="1"><nlm:affiliation>Karolinska Institutet, Stockholm, Sweden.</nlm:affiliation>
<country xml:lang="fr">Suède</country>
<wicri:regionArea>Karolinska Institutet, Stockholm</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Kamphuisen, P" sort="Kamphuisen, P" uniqKey="Kamphuisen P" first="P" last="Kamphuisen">P. Kamphuisen</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Vascular Medicine, University Medical Centre Groningen, University of Groningen, Groningen, the Netherlands.</nlm:affiliation>
<country xml:lang="fr" wicri:curation="lc">Pays-Bas</country>
<wicri:regionArea>Department of Vascular Medicine, University Medical Centre Groningen, University of Groningen, Groningen</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Debourdeau, P" sort="Debourdeau, P" uniqKey="Debourdeau P" first="P" last="Debourdeau">P. Debourdeau</name>
<affiliation wicri:level="1"><nlm:affiliation>Oncology Department, Ste Catherine Institute, Avignon, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Oncology Department, Ste Catherine Institute, Avignon</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Rigamonti, V" sort="Rigamonti, V" uniqKey="Rigamonti V" first="V" last="Rigamonti">V. Rigamonti</name>
<affiliation wicri:level="1"><nlm:affiliation>Praxis Bubenberg, Bern, Switzerland.</nlm:affiliation>
<country xml:lang="fr">Suisse</country>
<wicri:regionArea>Praxis Bubenberg, Bern</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Ortel, T L" sort="Ortel, T L" uniqKey="Ortel T" first="T L" last="Ortel">T L Ortel</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Hematology, Duke University Medical Center, Durham, NC, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Division of Hematology, Duke University Medical Center, Durham, NC</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Lee, A" sort="Lee, A" uniqKey="Lee A" first="A" last="Lee">A. Lee</name>
<affiliation wicri:level="1"><nlm:affiliation>Diamond Health Care Centre, University of British Columbia and Vancouver Coastal Health, Vancouver, BC, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Diamond Health Care Centre, University of British Columbia and Vancouver Coastal Health, Vancouver, BC</wicri:regionArea>
</affiliation>
</author>
</analytic>
<series><title level="j">Journal of thrombosis and haemostasis : JTH</title>
<idno type="eISSN">1538-7836</idno>
<imprint><date when="2015" type="published">2015</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term>
<term>Anticoagulants (administration & dosage)</term>
<term>Anticoagulants (adverse effects)</term>
<term>Chi-Square Distribution</term>
<term>Drug Substitution</term>
<term>Female</term>
<term>Hemorrhage (chemically induced)</term>
<term>Heparin, Low-Molecular-Weight (administration & dosage)</term>
<term>Heparin, Low-Molecular-Weight (adverse effects)</term>
<term>Humans</term>
<term>Kaplan-Meier Estimate</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Neoplasms (blood)</term>
<term>Neoplasms (complications)</term>
<term>Neoplasms (mortality)</term>
<term>Neoplasms (pathology)</term>
<term>Proportional Hazards Models</term>
<term>Prospective Studies</term>
<term>Recurrence</term>
<term>Registries</term>
<term>Retrospective Studies</term>
<term>Risk Factors</term>
<term>Time Factors</term>
<term>Treatment Outcome</term>
<term>Venous Thromboembolism (blood)</term>
<term>Venous Thromboembolism (diagnosis)</term>
<term>Venous Thromboembolism (drug therapy)</term>
<term>Venous Thromboembolism (etiology)</term>
<term>Venous Thromboembolism (mortality)</term>
<term>Vitamin K (antagonists & inhibitors)</term>
<term>Warfarin (administration & dosage)</term>
<term>Warfarin (adverse effects)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adulte d'âge moyen</term>
<term>Anticoagulants (administration et posologie)</term>
<term>Anticoagulants (effets indésirables)</term>
<term>Enregistrements</term>
<term>Estimation de Kaplan-Meier</term>
<term>Facteurs de risque</term>
<term>Facteurs temps</term>
<term>Femelle</term>
<term>Humains</term>
<term>Hémorragie ()</term>
<term>Héparine bas poids moléculaire (administration et posologie)</term>
<term>Héparine bas poids moléculaire (effets indésirables)</term>
<term>Loi du khi-deux</term>
<term>Modèles de hasards proportionnels</term>
<term>Mâle</term>
<term>Récidive</term>
<term>Résultat thérapeutique</term>
<term>Substitution de médicament</term>
<term>Sujet âgé</term>
<term>Thromboembolisme veineux (diagnostic)</term>
<term>Thromboembolisme veineux (mortalité)</term>
<term>Thromboembolisme veineux (sang)</term>
<term>Thromboembolisme veineux (traitement médicamenteux)</term>
<term>Thromboembolisme veineux (étiologie)</term>
<term>Tumeurs ()</term>
<term>Tumeurs (anatomopathologie)</term>
<term>Tumeurs (mortalité)</term>
<term>Tumeurs (sang)</term>
<term>Vitamine K (antagonistes et inhibiteurs)</term>
<term>Warfarine (administration et posologie)</term>
<term>Warfarine (effets indésirables)</term>
<term>Études prospectives</term>
<term>Études rétrospectives</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Anticoagulants</term>
<term>Heparin, Low-Molecular-Weight</term>
<term>Warfarin</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Anticoagulants</term>
<term>Heparin, Low-Molecular-Weight</term>
<term>Warfarin</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Vitamin K</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Anticoagulants</term>
<term>Héparine bas poids moléculaire</term>
<term>Warfarine</term>
</keywords>
<keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Tumeurs</term>
</keywords>
<keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Vitamine K</term>
</keywords>
<keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Neoplasms</term>
<term>Venous Thromboembolism</term>
</keywords>
<keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Hemorrhage</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Venous Thromboembolism</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Thromboembolisme veineux</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Venous Thromboembolism</term>
</keywords>
<keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Anticoagulants</term>
<term>Héparine bas poids moléculaire</term>
<term>Warfarine</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Venous Thromboembolism</term>
</keywords>
<keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Neoplasms</term>
<term>Venous Thromboembolism</term>
</keywords>
<keywords scheme="MESH" qualifier="mortalité" xml:lang="fr"><term>Thromboembolisme veineux</term>
<term>Tumeurs</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Thromboembolisme veineux</term>
<term>Tumeurs</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Thromboembolisme veineux</term>
</keywords>
<keywords scheme="MESH" qualifier="étiologie" xml:lang="fr"><term>Thromboembolisme veineux</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged</term>
<term>Chi-Square Distribution</term>
<term>Drug Substitution</term>
<term>Female</term>
<term>Humans</term>
<term>Kaplan-Meier Estimate</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Proportional Hazards Models</term>
<term>Prospective Studies</term>
<term>Recurrence</term>
<term>Registries</term>
<term>Retrospective Studies</term>
<term>Risk Factors</term>
<term>Time Factors</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adulte d'âge moyen</term>
<term>Enregistrements</term>
<term>Estimation de Kaplan-Meier</term>
<term>Facteurs de risque</term>
<term>Facteurs temps</term>
<term>Femelle</term>
<term>Humains</term>
<term>Hémorragie</term>
<term>Loi du khi-deux</term>
<term>Modèles de hasards proportionnels</term>
<term>Mâle</term>
<term>Récidive</term>
<term>Résultat thérapeutique</term>
<term>Substitution de médicament</term>
<term>Sujet âgé</term>
<term>Tumeurs</term>
<term>Études prospectives</term>
<term>Études rétrospectives</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Recommendations for management of cancer-related venous thromboembolism (VTE) in patients already receiving anticoagulant therapy are based on low-quality evidence. This international registry sought to provide more information on outcomes after a breakthrough VTE in relation to anticoagulation strategies.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25851122</PMID>
<DateCreated><Year>2015</Year>
<Month>06</Month>
<Day>02</Day>
</DateCreated>
<DateCompleted><Year>2016</Year>
<Month>02</Month>
<Day>25</Day>
</DateCompleted>
<DateRevised><Year>2015</Year>
<Month>06</Month>
<Day>02</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1538-7836</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>13</Volume>
<Issue>6</Issue>
<PubDate><Year>2015</Year>
<Month>Jun</Month>
</PubDate>
</JournalIssue>
<Title>Journal of thrombosis and haemostasis : JTH</Title>
<ISOAbbreviation>J. Thromb. Haemost.</ISOAbbreviation>
</Journal>
<ArticleTitle>Recurrent venous thromboembolism in anticoagulated patients with cancer: management and short-term prognosis.</ArticleTitle>
<Pagination><MedlinePgn>1010-8</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1111/jth.12955</ELocationID>
<Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Recommendations for management of cancer-related venous thromboembolism (VTE) in patients already receiving anticoagulant therapy are based on low-quality evidence. This international registry sought to provide more information on outcomes after a breakthrough VTE in relation to anticoagulation strategies.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">Patients with cancer and VTE despite anticoagulant therapy were reported to the registry. Data on treatments, VTE events, major bleeding, residual thrombosis symptoms and death were collected for the following 3 months. Breakthrough VTE and subsequent recurrences were objectively verified. Outcomes with different treatment strategies were compared with Cox proportional hazards regression.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">We registered 212 patients with breakthrough VTE. Of those, 59% had adenocarcinoma and 73% had known metastases. At the time of the breakthrough event, 70% were on low-molecular-weight heparin (LMWH) and 27% on a vitamin K antagonist (VKA); 70% had a therapeutic or supratherapeutic dose. After breakthrough the regimen was: unchanged therapeutic dose in 33%, dose increased in 31%, switched to another drug in 24%; and other management in 11%. During the following 3 months 11% had another VTE, 8% had major bleeding and 27% died. Of the survivors, 74% had residual thrombosis symptoms. Additional VTE recurrence was less common with LMWH than with a VKA (hazard ratio [HR], 0.28; 95% confidence interval [CI], 0.11-0.70) but similar with unchanged or increased anticoagulant intensity (HR, 1.09; 95% CI, 0.45-2.63). The bleeding rate did not increase significantly with dose escalation.</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Morbidity and mortality are high after recurrence of cancer-related VTE despite anticoagulation. Further treatment appears to be more effective with LMWH than with a VKA.</AbstractText>
<CopyrightInformation>© 2015 International Society on Thrombosis and Haemostasis.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schulman</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>Department of Medicine, McMaster University, Hamilton, ON, Canada.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Karolinska Institutet, Stockholm, Sweden.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Zondag</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Department of Medicine, McMaster University, Hamilton, ON, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Linkins</LastName>
<ForeName>L</ForeName>
<Initials>L</Initials>
<AffiliationInfo><Affiliation>Department of Medicine, McMaster University, Hamilton, ON, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Pasca</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>Center for Hemorrhagic and Thrombotic Disease, University Hospital of Udine, Udine, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Cheung</LastName>
<ForeName>Y W</ForeName>
<Initials>YW</Initials>
<AffiliationInfo><Affiliation>Academic Medical Centre, University of Amsterdam, Amsterdam, the Netherlands.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>de Sancho</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Weill Cornell Medical College, New York, NY, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Gallus</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Flinders University, Adelaide, SA, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Lecumberri</LastName>
<ForeName>R</ForeName>
<Initials>R</Initials>
<AffiliationInfo><Affiliation>Hematology Service, University Clinic of Navarra, Pamplona, Spain.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Molnar</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>Oncology and Hematology Department, Sanatorio Allende, Cordoba, Argentina.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Ageno</LastName>
<ForeName>W</ForeName>
<Initials>W</Initials>
<AffiliationInfo><Affiliation>Department of Clinical and Experimental Medicine, University of Insubria, Varese, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Le Gal</LastName>
<ForeName>G</ForeName>
<Initials>G</Initials>
<Identifier Source="ORCID">http://orcid.org/0000-0002-9253-248X</Identifier>
<AffiliationInfo><Affiliation>Department of Internal Medicine and Chest Diseases, Brest University Hospital, Brest, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Falanga</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Department of Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Hulegårdh</LastName>
<ForeName>E</ForeName>
<Initials>E</Initials>
<AffiliationInfo><Affiliation>Department of Hematology and Coagulation, Sahlgrenska University Hospital, Gothenburg, Sweden.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Ranta</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>Karolinska Institutet, Stockholm, Sweden.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Kamphuisen</LastName>
<ForeName>P</ForeName>
<Initials>P</Initials>
<AffiliationInfo><Affiliation>Department of Vascular Medicine, University Medical Centre Groningen, University of Groningen, Groningen, the Netherlands.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Debourdeau</LastName>
<ForeName>P</ForeName>
<Initials>P</Initials>
<AffiliationInfo><Affiliation>Oncology Department, Ste Catherine Institute, Avignon, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Rigamonti</LastName>
<ForeName>V</ForeName>
<Initials>V</Initials>
<AffiliationInfo><Affiliation>Praxis Bubenberg, Bern, Switzerland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Ortel</LastName>
<ForeName>T L</ForeName>
<Initials>TL</Initials>
<AffiliationInfo><Affiliation>Division of Hematology, Duke University Medical Center, Durham, NC, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Lee</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Diamond Health Care Centre, University of British Columbia and Vancouver Coastal Health, Vancouver, BC, Canada.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2015</Year>
<Month>05</Month>
<Day>09</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>England</Country>
<MedlineTA>J Thromb Haemost</MedlineTA>
<NlmUniqueID>101170508</NlmUniqueID>
<ISSNLinking>1538-7836</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D006495">Heparin, Low-Molecular-Weight</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>12001-79-5</RegistryNumber>
<NameOfSubstance UI="D014812">Vitamin K</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>5Q7ZVV76EI</RegistryNumber>
<NameOfSubstance UI="D014859">Warfarin</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000925" MajorTopicYN="N">Anticoagulants</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016009" MajorTopicYN="N">Chi-Square Distribution</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D057915" MajorTopicYN="N">Drug Substitution</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006470" MajorTopicYN="N">Hemorrhage</DescriptorName>
<QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006495" MajorTopicYN="N">Heparin, Low-Molecular-Weight</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D053208" MajorTopicYN="N">Kaplan-Meier Estimate</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
<QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
<QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016016" MajorTopicYN="N">Proportional Hazards Models</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012042" MajorTopicYN="N">Registries</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D054556" MajorTopicYN="N">Venous Thromboembolism</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
<QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
<QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014812" MajorTopicYN="N">Vitamin K</DescriptorName>
<QualifierName UI="Q000037" MajorTopicYN="N">antagonists & inhibitors</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014859" MajorTopicYN="N">Warfarin</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">bleeding</Keyword>
<Keyword MajorTopicYN="N">cancer</Keyword>
<Keyword MajorTopicYN="N">low-molecular-weight heparin</Keyword>
<Keyword MajorTopicYN="N">venous thromboembolism</Keyword>
<Keyword MajorTopicYN="N">warfarin</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year>
<Month>12</Month>
<Day>19</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2015</Year>
<Month>03</Month>
<Day>29</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2015</Year>
<Month>4</Month>
<Day>9</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2015</Year>
<Month>4</Month>
<Day>9</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2016</Year>
<Month>2</Month>
<Day>26</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">25851122</ArticleId>
<ArticleId IdType="doi">10.1111/jth.12955</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002C54 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 002C54 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Asie |area= AustralieFrV1 |flux= PubMed |étape= Curation |type= RBID |clé= pubmed:25851122 |texte= Recurrent venous thromboembolism in anticoagulated patients with cancer: management and short-term prognosis. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:25851122" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \ | NlmPubMed2Wicri -a AustralieFrV1
This area was generated with Dilib version V0.6.33. |